Posted by Michael Wonder on 14 Sep 2018
Ironwood Pharmaceuticals announces FDA fast track designation for praliciguat for the treatment of heart failure with preserved ejection fraction
13 September 2018 - Praliciguat Phase II trial in HFpEF continues to enrol patients with top-line data expected in the second half of 2019.
Ironwood Pharmaceuticals today announced that the U.S. FDA has granted Fast Track Designation for praliciguat (IW-1973) for the treatment of patients with heart failure with preserved ejection fraction (HFpEF). Praliciguat is an investigational, orally administered soluble guanylate cyclase stimulator currently in Phase II clinical trials.
Ironwood is currently enrolling patients in a randomized, double-blind, placebo-controlled Phase II trial evaluating praliciguat for the potential treatment of HFpEF.
